Compare UK prices. 40+ products · 17 retailers scored
PeptideClear UK

ICB · NHS GLP-1 access

Nottingham and Nottinghamshire: NHS GLP-1 access

NHS Nottingham and Nottinghamshire ICB (N&N) is the NHS England Integrated Care Board for Nottingham, Mansfield, Newark and the surrounding area, serving approximately 1.16 million people across the Midlands region. NICE Mounjaro rollout under TA1026 is operationalised here through the local Specialist Weight Management Service. Cohort 1 (BMI 40+ with 4+ comorbidities) is live nationally since June 2025; Cohort 2 launches across England on 23 June 2026.

POM: Prescription only medicine (POM). PeptideClear is a comparison and information service. We do not prescribe, dispense, or recommend medication for individuals. A qualified GMC-registered prescriber determines suitability after consultation.

Region

Midlands

Population served

~1.16m

ICB abbreviation

N&N

Major areas covered

Nottingham · Mansfield · Newark · Worksop · Beeston

Strong tertiary care anchor at Nottingham University Hospitals. Mining-belt patches in the north of the county have elevated comorbidity prevalence.

Rollout cohort framework (national)

Local pace varies. Some ICBs commissioned tier-3 capacity ahead of June 2025 and ran ready; others took six to twelve months to scale. Capacity at the local Specialist Weight Management Service is the binding constraint in most areas. PeptideClear\'s central rollout tracker documents known pace data per region; per-ICB granular data is added as ICBs publish.

How NHS referral works in Nottingham and Nottinghamshire

The standard NHS pathway for patients meeting current-cohort criteria starts with the GP. The GP confirms BMI, ethnicity adjustment where applicable, and comorbidity count, then refers to the local Specialist Weight Management Service. The service runs the assessment, prescribes the medication if the patient is suitable, and provides the structured 12-month programme that includes lifestyle support alongside the medication.

Stopping rule: patients must achieve at least 5 percent weight loss from baseline by month 6 for NHS Mounjaro to continue under TA1026. Private prescribing operates outside this stopping rule and follows its own continuation criteria.

Private alternatives

Private prescribing operates independently of the NHS cohort framework. UK clinics and pharmacies can prescribe tirzepatide and semaglutide based on their own clinical criteria, typically aligned to MHRA SPCs (BMI 30+ for Wegovy, BMI 30+ for Mounjaro weight management, BMI 27+ with comorbidities).

Neighbouring ICBs

Background reading

PeptideClear is editorial. We do not prescribe, dispense, or sell prescription medication. Your prescriber decides what medication and dose suits you.

Reviewed by Oliver Mackman, editorial director · last reviewed 2026-05-20